Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 25.01.2022 at 12:00 PM CET
Settings

Settings

Goto Application

1. WO2022007284 - USE OF CALCIUM CHANNEL INHIBITOR OXOGLAUCINE IN OSTEOARTHRITIS

Publication Number WO/2022/007284
Publication Date 13.01.2022
International Application No. PCT/CN2020/127493
International Filing Date 09.11.2020
IPC
A61K 31/473 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
47Quinolines; Isoquinolines
473ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
A61P 19/02 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
19Drugs for skeletal disorders
02for joint disorders, e.g. arthritis, arthrosis
A61P 29/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
29Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (NSAIDs)
Applicants
  • 深圳市臻质医疗科技有限公司 GENEO MEDICINE CO., LTD. [CN]/[CN]
Inventors
  • 钟刚 ZHONG, Gang
  • 于寅 YU, Yin
  • 张耶明 ZHANG, Yeming
Agents
  • 广州市南锋专利事务所有限公司 GUANGZHOU NANFENG PATENT AGENT LTD. CO.
  • 张鹏 ZHANG, Peng
Priority Data
202010664513.810.07.2020CN
Publication Language Chinese (zh)
Filing Language Chinese (ZH)
Designated States
Title
(EN) USE OF CALCIUM CHANNEL INHIBITOR OXOGLAUCINE IN OSTEOARTHRITIS
(FR) UTILISATION DE L'OXOGLAUCINE, INHIBITEUR DE CANAUX CALCIQUES, DANS L'ARTHROSE
(ZH) 一种钙通道抑制剂氧海罂粟碱在骨关节炎中的应用
Abstract
(EN) Oxoglaucine is found to be a novel calcium channel TRPV5 inhibitor. Cell experiments confirm that the oxoglaucine can significantly inhibit the expression of TRPV5 and key indicators downstream thereof. Animal experiments further confirm that the oxoglaucine can significantly inhibit the apoptosis of osteoarthritis chondrocyte and the expression of inflammatory mediators. Therefore, the oxoglaucine can be used in the preparation of a drug for treating osteoarthritis, which has great significance in exerting the treatment effect of the oxoglaucine on the osteoarthritis, and has a wide application prospect.
(FR) Il a été découvert que l'oxoglaucine est un nouvel inhibiteur des canaux calciques TRPV5. Des expériences cellulaires confirment que l'oxoglaucine peut inhiber considérablement l'expression de TRPV5 et des indicateurs clés en aval de ce dernier. Des expériences animales confirment en outre que l'oxoglaucine peut inhiber de manière considérable l'apoptose des chondrocytes de l'arthrose et l'expression de médiateurs inflammatoires. Par conséquent, l'oxoglaucine peut être utilisée dans la préparation d'un médicament destiné au traitement de l'arthrose, qui a une grande importance pour exercer l'effet de traitement de l'oxoglaucine sur l'arthrose, et présente de larges perspectives d'application.
(ZH) 发现氧海罂粟碱是一种新型的钙通道TRPV5抑制剂,并通过细胞实验证实了氧海罂粟碱能够显著抑制TRPV5及其下游的关键指标的表达,并进一步通过动物实验证实了氧海罂粟碱能显著抑制骨关节炎软骨细胞凋亡和炎症介质的表达。因此,氧海罂粟碱可用于制备治疗骨关节炎的药物,对发挥氧海罂粟在骨关节炎的治疗作用上具有重大意义,具有广阔的应用前景。
Related patent documents
Latest bibliographic data on file with the International Bureau